

[4] MOURAD J J, DES GUETZ G, DEBBABI H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation [J]. *Ann Oncol*, 2008, 19 (5): 927-934.

[5] SANE D C, ANTON L, BROSNIHAN K B. Angiogenic growth factors and hypertension [J]. *Angiogenesis*, 2004, 7 (3): 193-201.

[6] HOROWITZ J R, RIVARD A, VAN DER ZEE R, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide - dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium [J]. *Arterioscler Thromb Vasc Biol*, 1997, 17 (11): 2793-2800.

[7] DAHLBERG S E, SANDLER A B, BRAHMER J R, et al. Clinical course of advanced non - small - cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 [J]. *J Clin Oncol*, 2010, 28 (6): 949-954.

[8] SCARTOZZI M, GALIZIA E, CHIORRINI S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first - line bevacizumab [J]. *Ann Oncol*, 2009, 20 (2): 227-230.

[9] ÖSTERLUND P, SOVERI L M, ISONIEMI H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab - containing chemotherapy [J]. *Br J Cancer*, 2011, 104 (4): 599-604.

[10] DEWDNEY A, CUNNINGHAM D, BARBACHANO Y, et al. Correlation of bevacizumab - induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri - operative treatment in 45 patients with poor - risk colorectal liver - only metastases unsuitable for upfront resection [J]. *Br J Cancer*, 2012, 106 (11): 1718-1721.

[11] RANPURA V, HAPANI S, WU S. Treatment - related mortality with bevacizumab in cancer patients: a meta - analysis [J]. *JAMA*, 2011, 305 (5): 487-494.

[12] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours; revised RECIST guideline (version 1.1) [J]. *Eur J Cancer*, 2009, 45 (2): 228-247.

[13] CAMPO R A, AGARWAL N, LASTAYO P C, et al. Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12 - week randomized controlled trial of Qigong [J]. *J Cancer Surviv*, 2014, 8 (1): 60-69.

[14] MIR O, CORIAT R, CABANES L, et al. An observational study of bevacizumab - induced hypertension as a clinical biomarker of antitumor activity [J]. *Oncologist*, 2011, 16 (9): 1325-1332.

[15] HURWITZ H I, DOUGLAS P S, MIDDLETON J P, et al. Analysis of early hypertension and clinical outcome with bevacizumab; results from seven phase III studies [J]. *Oncologist*, 2013, 18 (3): 273-280.

[16] RECK M, VON PAWEL J, ZATLOUKAL P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first - line therapy for nonsquamous non - small - cell lung cancer; AVAiL [J]. *J Clin Oncol*, 2009, 27 (8): 1227-1234.

(收稿日期: 2016-08-09; 修回日期: 2016-11-16)

(本文编辑: 李洁晨)

## · 从医者说 ·

### 从医生的角度谈“人性”，说的太好了！

今天看了一部韩国电影《隧道》，讲的是隧道塌方后的求生故事：刚建好一年的穿山隧道突然坍塌，开车经过的男主被压在山下，媒体蜂拥而至争相报道，政客们瞬间聚集于此以捞取政治资本，并举全韩国之力实施营救；而随着物资消耗及人员伤亡，媒体们的关注点开始转向能否打破生存记录，政客们不耐烦地回答着重重复的问题，民众甚至也开始怀疑耗费如此之大的人力物力来救一个不知是否存活的人是否值得。此刻，片中所有曾带来人性温暖的角色：政府官员、媒体、民众……全都变成冷冰冰的存在。

以这部电影开场是想引出我对人性的看法 - 既不是白，也不是黑，而是灰色，而性善论和性恶论皆不足以覆盖人性 - 人性从来不是非黑即白，人性太复杂了，尤其在生死攸关的问题上。舆论把医生的道德水准绑架得很高，导致民众甚至医生自己都产生了一种医生必须无私奉献的错觉！医生和每一个社会个体一样，即便普遍学历较高，也绝未达到不食人间烟火的境界。粗暴地把医生划分为自私和无私是愚蠢的，一味地要求医生道德纯洁无暇未免强人所难。道德的绑架必然衍生出不求回报的无理要求：医生不能挣钱，或者说医生挣了钱就会招致仇恨。有人说，金钱是万恶的根源，但没有钱谁也不能活下去；要我说，金钱不是罪恶的，没能力处理金钱才是罪恶的温床。我们换个提法：善良的人不能挣钱，因为挣钱“不善良”，排开医生不论，这样的说法能否让人信服和首肯呢？

诚然，面临困境的不止医生，患者也同样难堪。医闹、医暴把医患关系破坏到极致，也把患者推到风口浪尖。患者何尝不是受了莫大的委屈？每个人都会生病，一生中必然要和医生打交道，医患之间如果是敌对关系，那么结果只能是双输。我所见过的医生，90%以上都会为患者着想，从不挣昧良心钱，而他们的正当收入及辛苦付出理应受到保护和尊重。不必去歌颂，也不必去抹黑，人与人相处，将心比心，脱离医生与患者的角色，医患关系无非就是人与人打交道，对彼此宽容一点，也许就是人与人之间最大的恩惠。

(来源: 医脉通; 作者: 王明宇)